uniQure N.V.
$6.51
29
+$0+0% Tuesday 17:15
Statistik
Harga Tertinggi Hari
6.83
Harga Terendah Hari
6.28
52M Tertinggi
22.2
52M Terendah
4.94
Volum
3,094
Volum Purata
2,359
Kapasiti Pasaran
-
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
29OctDijangka
EPS yang dijangka
-0.992736
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 0EE0.LSE. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Sangamo Therapeutics
SGMO
Kapasiti Pasaran176.57M
Bluebird bio
BLUE
Kapasiti Pasaran108.22M
Biomarin Pharmaceutical
BMRN
Kapasiti Pasaran17.36B
Pfizer
PFE
Kapasiti Pasaran164.39B
Regenxbio
RGNX
Kapasiti Pasaran603.95M
Sarepta Therapeutics
SRPT
Kapasiti Pasaran12.95B
Intellia Therapeutics
NTLA
Kapasiti Pasaran2.28B
CRISPR Therapeutics
CRSP
Kapasiti Pasaran4.06B
Mengenai
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Show more...
CEO
Mr. Matthew Craig Kapusta
Pekerja
463
Negara
NL
ISIN
NL0010696654